Form 4: Exact Sciences Director Sells Shares Post-Merger

Kimberly J. Popovits, a director at Exact Sciences Corp., disposed of all her common stock holdings following the company's merger with a subsidiary of Abbott Laboratories.

Summary

• Kimberly J. Popovits, a Director of Exact Sciences Corp. (EXAS), reported changes in beneficial ownership.
• On March 23, 2026, Exact Sciences Corporation merged with Badger Merger Sub I, Inc., a direct, wholly-owned subsidiary of Abbott Laboratories.
• At the effective time of the Merger, each share of Exact Sciences' common stock, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest.
• Ms. Popovits disposed of 6,725 shares and then 9,656 shares of common stock on March 23, 2026, resulting in 0 shares beneficially owned following the reported transactions.
• Shares of common stock subject to vesting, repurchase, or other lapse restrictions, granted under an Issuer stock plan, were deemed fully vested and cancelled, converting into the right to receive the Merger Consideration, less any applicable tax withholding.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Exact Sciences shareholders, who received a significant cash payout, and for Abbott Laboratories, which expanded its diagnostics portfolio.

Positives

• Shareholders of Exact Sciences Corporation received a cash consideration of $105.00 per share, indicating a favorable valuation for their equity.
• Restricted stock units held by employees and directors were fully vested and converted into cash, providing a clear benefit upon the change of control.

Negatives

• Exact Sciences Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Abbott Laboratories.
• Existing shareholders no longer hold equity in Exact Sciences, as their shares were converted into cash.

Risks

• The company is no longer publicly traded, removing direct investment opportunities in EXAS common stock.

Future Outlook

Exact Sciences Corporation is now a wholly-owned subsidiary of Abbott Laboratories, and its future outlook is integrated into Abbott's overall strategic plans and financial reporting.

Industry Context

StockSavvy.ai notes that this acquisition by Abbott Laboratories highlights a trend of larger pharmaceutical and medical device companies integrating specialized diagnostic firms to expand their portfolios, particularly in areas like cancer screening where Exact Sciences has a strong presence with products like Cologuard. This move strengthens Abbott's position in the diagnostics market.

Comparison to Industry Standards

• The $105.00 per share cash consideration should be evaluated against recent M&A multiples (e.g., EV/Revenue, P/E) for comparable diagnostic companies like Guardant Health (GH), Natera (NTRA), or Veracyte (VCYT) at the time of the merger agreement (November 2025) to assess if it represents a typical premium for a strategic acquisition in the diagnostics space.
• The full vesting of restricted stock units is a standard practice in change-of-control provisions, aligning executive and employee incentives with shareholder value realization during an acquisition.

Stakeholder Impact

• Shareholders: Received $105.00 per share in cash, ceasing to be shareholders of Exact Sciences.
• Employees (holding restricted stock): Restricted stock fully vested and converted to cash.
• Exact Sciences as an entity: Became a wholly-owned subsidiary of Abbott Laboratories.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Acquisition, Form 4, Insider Transaction, Director Stock Sale, Corporate Action, Healthcare M&A